RayKnowChina Research Map
Shortlist0

RecruitingHepatocellular carcinomaStomach cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis

An open trial on hepatocellular carcinoma and stomach cancer, registered on ClinicalTrials.gov. Led by Second Affiliated Hospital, Zhejiang University; 3 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

Read the record on ClinicalTrials.gov

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 4

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  2. Study siteFirst Affiliated Hospital of Nanchang University南昌大学第一附属医院NanchangHospital page
  3. Study siteHuashan Hospital复旦大学附属华山医院ShanghaiHospital page
  4. Study siteSecond Affiliated Hospital of Nanchang University南昌大学第二附属医院NanchangHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06822413, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.
  • Patients in normal physiological conditions without any malignant tumors or precancerous lesions.
  • Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.
  • Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.

Exclusion Criteria:

  • Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time
  • Post-cancer treatment patients.

Quoted from ClinicalTrials.gov, NCT06822413, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06822413, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06822413